HEADER TRANSCRIPTION 19-SEP-19 6KYP TITLE X-RAY STRUCTURE OF HUMAN PPARALPHA LIGAND BINDING DOMAIN-GW9662- TITLE 2 CLOFIBRIC ACID CO-CRYSTALS OBTAINED BY DELIPIDATION AND CO- TITLE 3 CRYSTALLIZATION COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA; COMPND 3 CHAIN: A, B; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_TAXID: 9606; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 7 EXPRESSION_SYSTEM_PLASMID: PET28A KEYWDS NUCLEAR RECEPTOR, PROTEIN-LIGAND COMPLEX, PPAR, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR S.KAMATA,K.SAITO,A.HONDA,R.ISHIKAWA,T.OYAMA,I.ISHII REVDAT 4 22-NOV-23 6KYP 1 REMARK REVDAT 3 02-DEC-20 6KYP 1 JRNL REVDAT 2 25-NOV-20 6KYP 1 TITLE REVDAT 1 11-NOV-20 6KYP 0 JRNL AUTH S.KAMATA,T.OYAMA,K.SAITO,A.HONDA,Y.YAMAMOTO,K.SUDA, JRNL AUTH 2 R.ISHIKAWA,T.ITOH,Y.WATANABE,T.SHIBATA,K.UCHIDA,M.SUEMATSU, JRNL AUTH 3 I.ISHII JRNL TITL PPAR ALPHA LIGAND-BINDING DOMAIN STRUCTURES WITH ENDOGENOUS JRNL TITL 2 FATTY ACIDS AND FIBRATES. JRNL REF ISCIENCE V. 23 01727 2020 JRNL REFN ESSN 2589-0042 JRNL PMID 33205029 JRNL DOI 10.1016/J.ISCI.2020.101727 REMARK 2 REMARK 2 RESOLUTION. 2.86 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.11.1-2575-000 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.86 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 36.62 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.930 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.4 REMARK 3 NUMBER OF REFLECTIONS : 17130 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.198 REMARK 3 R VALUE (WORKING SET) : 0.195 REMARK 3 FREE R VALUE : 0.244 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.980 REMARK 3 FREE R VALUE TEST SET COUNT : 1636 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 2.9441 - 2.8600 0.97 2604 102 0.2967 0.3506 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.400 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.680 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : NULL NULL REMARK 3 ANGLE : NULL NULL REMARK 3 CHIRALITY : NULL NULL REMARK 3 PLANARITY : NULL NULL REMARK 3 DIHEDRAL : NULL NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: SF FILE CONTAINS FRIEDEL PAIRS UNDER REMARK 3 I/F_MINUS AND I/F_PLUS COLUMNS. REMARK 4 REMARK 4 6KYP COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 30-SEP-19. REMARK 100 THE DEPOSITION ID IS D_1300013867. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-JUN-18 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PHOTON FACTORY REMARK 200 BEAMLINE : BL-5A REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00000 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS3 S 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS 0.5.21 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 17144 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.860 REMARK 200 RESOLUTION RANGE LOW (A) : 46.840 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.6 REMARK 200 DATA REDUNDANCY : 3.400 REMARK 200 R MERGE (I) : 0.06500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.86 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.01 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.50 REMARK 200 R MERGE FOR SHELL (I) : 0.31400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER 2.7.16 REMARK 200 STARTING MODEL: 3VI8 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.67 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.05 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1 M TRIS (PH 8.5), 25 %(W/V) REMARK 280 PEG3350, VAPOR DIFFUSION, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 51.23900 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 196 REMARK 465 SER A 197 REMARK 465 HIS A 198 REMARK 465 GLY B 196 REMARK 465 SER B 197 REMARK 465 HIS B 198 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 232 CD CE NZ REMARK 470 LYS B 232 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 234 141.04 172.99 REMARK 500 CYS A 384 30.67 -89.01 REMARK 500 MET A 467 -77.16 -90.26 REMARK 500 THR B 200 -169.96 -65.61 REMARK 500 ALA B 233 11.90 -143.42 REMARK 500 SER B 234 134.89 -179.64 REMARK 500 LEU B 254 42.61 -88.92 REMARK 500 ASP B 419 77.35 -104.60 REMARK 500 ALA B 455 -171.47 -61.09 REMARK 500 HIS B 457 136.71 -39.18 REMARK 500 MET B 467 -77.87 -63.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GW9 A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GW9 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GW9 A 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue E0O B 504 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide GW9 B 501 and CYS B REMARK 800 276 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide GW9 B 502 and CYS B REMARK 800 275 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide GW9 B 503 and CYS B REMARK 800 278 DBREF 6KYP A 200 468 UNP Q07869 PPARA_HUMAN 200 468 DBREF 6KYP B 200 468 UNP Q07869 PPARA_HUMAN 200 468 SEQADV 6KYP GLY A 196 UNP Q07869 EXPRESSION TAG SEQADV 6KYP SER A 197 UNP Q07869 EXPRESSION TAG SEQADV 6KYP HIS A 198 UNP Q07869 EXPRESSION TAG SEQADV 6KYP MET A 199 UNP Q07869 EXPRESSION TAG SEQADV 6KYP GLY B 196 UNP Q07869 EXPRESSION TAG SEQADV 6KYP SER B 197 UNP Q07869 EXPRESSION TAG SEQADV 6KYP HIS B 198 UNP Q07869 EXPRESSION TAG SEQADV 6KYP MET B 199 UNP Q07869 EXPRESSION TAG SEQRES 1 A 273 GLY SER HIS MET THR ALA ASP LEU LYS SER LEU ALA LYS SEQRES 2 A 273 ARG ILE TYR GLU ALA TYR LEU LYS ASN PHE ASN MET ASN SEQRES 3 A 273 LYS VAL LYS ALA ARG VAL ILE LEU SER GLY LYS ALA SER SEQRES 4 A 273 ASN ASN PRO PRO PHE VAL ILE HIS ASP MET GLU THR LEU SEQRES 5 A 273 CYS MET ALA GLU LYS THR LEU VAL ALA LYS LEU VAL ALA SEQRES 6 A 273 ASN GLY ILE GLN ASN LYS GLU ALA GLU VAL ARG ILE PHE SEQRES 7 A 273 HIS CYS CYS GLN CYS THR SER VAL GLU THR VAL THR GLU SEQRES 8 A 273 LEU THR GLU PHE ALA LYS ALA ILE PRO GLY PHE ALA ASN SEQRES 9 A 273 LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY SEQRES 10 A 273 VAL TYR GLU ALA ILE PHE ALA MET LEU SER SER VAL MET SEQRES 11 A 273 ASN LYS ASP GLY MET LEU VAL ALA TYR GLY ASN GLY PHE SEQRES 12 A 273 ILE THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE SEQRES 13 A 273 CYS ASP ILE MET GLU PRO LYS PHE ASP PHE ALA MET LYS SEQRES 14 A 273 PHE ASN ALA LEU GLU LEU ASP ASP SER ASP ILE SER LEU SEQRES 15 A 273 PHE VAL ALA ALA ILE ILE CYS CYS GLY ASP ARG PRO GLY SEQRES 16 A 273 LEU LEU ASN VAL GLY HIS ILE GLU LYS MET GLN GLU GLY SEQRES 17 A 273 ILE VAL HIS VAL LEU ARG LEU HIS LEU GLN SER ASN HIS SEQRES 18 A 273 PRO ASP ASP ILE PHE LEU PHE PRO LYS LEU LEU GLN LYS SEQRES 19 A 273 MET ALA ASP LEU ARG GLN LEU VAL THR GLU HIS ALA GLN SEQRES 20 A 273 LEU VAL GLN ILE ILE LYS LYS THR GLU SER ASP ALA ALA SEQRES 21 A 273 LEU HIS PRO LEU LEU GLN GLU ILE TYR ARG ASP MET TYR SEQRES 1 B 273 GLY SER HIS MET THR ALA ASP LEU LYS SER LEU ALA LYS SEQRES 2 B 273 ARG ILE TYR GLU ALA TYR LEU LYS ASN PHE ASN MET ASN SEQRES 3 B 273 LYS VAL LYS ALA ARG VAL ILE LEU SER GLY LYS ALA SER SEQRES 4 B 273 ASN ASN PRO PRO PHE VAL ILE HIS ASP MET GLU THR LEU SEQRES 5 B 273 CYS MET ALA GLU LYS THR LEU VAL ALA LYS LEU VAL ALA SEQRES 6 B 273 ASN GLY ILE GLN ASN LYS GLU ALA GLU VAL ARG ILE PHE SEQRES 7 B 273 HIS CYS CYS GLN CYS THR SER VAL GLU THR VAL THR GLU SEQRES 8 B 273 LEU THR GLU PHE ALA LYS ALA ILE PRO GLY PHE ALA ASN SEQRES 9 B 273 LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY SEQRES 10 B 273 VAL TYR GLU ALA ILE PHE ALA MET LEU SER SER VAL MET SEQRES 11 B 273 ASN LYS ASP GLY MET LEU VAL ALA TYR GLY ASN GLY PHE SEQRES 12 B 273 ILE THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE SEQRES 13 B 273 CYS ASP ILE MET GLU PRO LYS PHE ASP PHE ALA MET LYS SEQRES 14 B 273 PHE ASN ALA LEU GLU LEU ASP ASP SER ASP ILE SER LEU SEQRES 15 B 273 PHE VAL ALA ALA ILE ILE CYS CYS GLY ASP ARG PRO GLY SEQRES 16 B 273 LEU LEU ASN VAL GLY HIS ILE GLU LYS MET GLN GLU GLY SEQRES 17 B 273 ILE VAL HIS VAL LEU ARG LEU HIS LEU GLN SER ASN HIS SEQRES 18 B 273 PRO ASP ASP ILE PHE LEU PHE PRO LYS LEU LEU GLN LYS SEQRES 19 B 273 MET ALA ASP LEU ARG GLN LEU VAL THR GLU HIS ALA GLN SEQRES 20 B 273 LEU VAL GLN ILE ILE LYS LYS THR GLU SER ASP ALA ALA SEQRES 21 B 273 LEU HIS PRO LEU LEU GLN GLU ILE TYR ARG ASP MET TYR HET GW9 A 501 27 HET GW9 A 502 27 HET GW9 A 503 27 HET GW9 B 501 27 HET GW9 B 502 27 HET GW9 B 503 27 HET E0O B 504 24 HETNAM GW9 2-CHLORO-5-NITRO-N-PHENYLBENZAMIDE HETNAM E0O 2-(4-CHLORANYLPHENOXY)-2-METHYL-PROPANOIC ACID FORMUL 3 GW9 6(C13 H9 CL N2 O3) FORMUL 9 E0O C10 H11 CL O3 HELIX 1 AA1 THR A 200 PHE A 218 1 19 HELIX 2 AA2 ASN A 221 GLY A 231 1 11 HELIX 3 AA3 ASP A 243 LYS A 252 1 10 HELIX 4 AA4 LEU A 254 ASN A 261 1 8 HELIX 5 AA5 GLU A 267 LYS A 292 1 26 HELIX 6 AA6 ASP A 301 SER A 322 1 22 HELIX 7 AA7 ARG A 341 LEU A 347 1 7 HELIX 8 AA8 PRO A 350 ILE A 354 5 5 HELIX 9 AA9 MET A 355 ALA A 367 1 13 HELIX 10 AB1 ASP A 371 CYS A 384 1 14 HELIX 11 AB2 ASN A 393 HIS A 416 1 24 HELIX 12 AB3 PHE A 421 GLU A 451 1 31 HELIX 13 AB4 HIS A 457 ARG A 465 1 9 HELIX 14 AB5 ALA B 201 PHE B 218 1 18 HELIX 15 AB6 ASN B 221 GLY B 231 1 11 HELIX 16 AB7 ASP B 243 LYS B 252 1 10 HELIX 17 AB8 LEU B 254 ASN B 261 1 8 HELIX 18 AB9 GLU B 267 ALA B 293 1 27 HELIX 19 AC1 ASP B 301 SER B 322 1 22 HELIX 20 AC2 ARG B 341 LEU B 347 1 7 HELIX 21 AC3 PHE B 351 LEU B 368 1 18 HELIX 22 AC4 ASP B 371 CYS B 384 1 14 HELIX 23 AC5 ASN B 393 HIS B 416 1 24 HELIX 24 AC6 PHE B 421 THR B 450 1 30 HELIX 25 AC7 HIS B 457 ARG B 465 1 9 SHEET 1 AA1 4 PHE A 239 ILE A 241 0 SHEET 2 AA1 4 GLY A 337 THR A 340 1 O PHE A 338 N ILE A 241 SHEET 3 AA1 4 GLY A 329 VAL A 332 -1 N VAL A 332 O GLY A 337 SHEET 4 AA1 4 MET A 325 ASN A 326 -1 N ASN A 326 O GLY A 329 SHEET 1 AA2 4 PHE B 239 ILE B 241 0 SHEET 2 AA2 4 GLY B 337 THR B 340 1 O PHE B 338 N ILE B 241 SHEET 3 AA2 4 GLY B 329 VAL B 332 -1 N VAL B 332 O GLY B 337 SHEET 4 AA2 4 MET B 325 ASN B 326 -1 N ASN B 326 O GLY B 329 LINK SG CYS A 275 C9 GW9 A 502 1555 1555 1.80 LINK SG CYS A 276 C9 GW9 A 501 1555 1555 1.80 LINK SG CYS A 278 C9 GW9 A 503 1555 1555 1.80 LINK SG CYS B 275 C9 GW9 B 502 1555 1555 1.80 LINK SG CYS B 276 C9 GW9 B 501 1555 1555 1.80 LINK SG CYS B 278 C9 GW9 B 503 1555 1555 1.80 CISPEP 1 LYS A 349 PRO A 350 0 -0.29 CISPEP 2 LYS B 349 PRO B 350 0 1.81 SITE 1 AC1 6 ILE A 241 CYS A 276 LEU A 321 MET A 330 SITE 2 AC1 6 VAL A 332 GW9 A 502 SITE 1 AC2 7 ALA A 250 GLU A 251 LEU A 254 CYS A 275 SITE 2 AC2 7 ALA A 333 TYR A 334 GW9 A 501 SITE 1 AC3 8 LEU A 254 LYS A 257 LEU A 258 ASN A 261 SITE 2 AC3 8 HIS A 274 CYS A 275 CYS A 278 HIS A 457 SITE 1 AC4 9 PHE B 273 GLN B 277 SER B 280 TYR B 314 SITE 2 AC4 9 PHE B 318 LEU B 321 MET B 355 HIS B 440 SITE 3 AC4 9 TYR B 464 SITE 1 AC5 12 ILE B 241 ILE B 272 PHE B 273 HIS B 274 SITE 2 AC5 12 CYS B 275 GLN B 277 CYS B 278 THR B 279 SITE 3 AC5 12 SER B 280 LEU B 321 LEU B 331 GW9 B 502 SITE 1 AC6 14 PHE A 421 ALA B 250 GLU B 251 LEU B 254 SITE 2 AC6 14 ARG B 271 ILE B 272 PHE B 273 HIS B 274 SITE 3 AC6 14 CYS B 276 GLN B 277 CYS B 278 THR B 279 SITE 4 AC6 14 TYR B 334 GW9 B 501 SITE 1 AC7 14 LEU B 254 LYS B 257 LEU B 258 ASN B 261 SITE 2 AC7 14 ILE B 263 HIS B 274 CYS B 275 CYS B 276 SITE 3 AC7 14 GLN B 277 THR B 279 SER B 280 VAL B 281 SITE 4 AC7 14 GLU B 282 HIS B 457 CRYST1 60.710 102.478 61.465 90.00 100.15 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016472 0.000000 0.002949 0.00000 SCALE2 0.000000 0.009758 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016528 0.00000